Abstract
The smallest independently folded antibody fragments, the domains, are emerging as promising scaffolds for candidate therapeutics and diagnostics that bind specifically targets of interest. The discovery of such binders is based on several technologies including structure-based design and generation of libraries of mutants displayed on phage or yeast, next-generation sequencing for diversity analysis, panning and screening of the libraries, affinity maturation of selected binders, and their expression, purification, and characterization for specific binding, function, and aggregation propensity. In this review, we describe these technologies as applied for the generation of engineered antibody domains (eAds), especially those derived from the human immunoglobulin heavy chain variable region (VH) and the second domain of IgG1 heavy chain constant region (CH2) as potential candidate therapeutics and diagnostics, and discuss examples of eAds against HIV-1 and cancer-related proteins.
Keywords: Antibody domains, human, library, phage display, scaffold, stability, therapeutics, yeast display.
Current Drug Discovery Technologies
Title:Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains
Volume: 11 Issue: 1
Author(s): Weizao Chen, Rui Gong, Tianlei Ying, Ponraj Prabakaran, Zhongyu Zhu, Yang Feng and Dimiter S. Dimitrov
Affiliation:
Keywords: Antibody domains, human, library, phage display, scaffold, stability, therapeutics, yeast display.
Abstract: The smallest independently folded antibody fragments, the domains, are emerging as promising scaffolds for candidate therapeutics and diagnostics that bind specifically targets of interest. The discovery of such binders is based on several technologies including structure-based design and generation of libraries of mutants displayed on phage or yeast, next-generation sequencing for diversity analysis, panning and screening of the libraries, affinity maturation of selected binders, and their expression, purification, and characterization for specific binding, function, and aggregation propensity. In this review, we describe these technologies as applied for the generation of engineered antibody domains (eAds), especially those derived from the human immunoglobulin heavy chain variable region (VH) and the second domain of IgG1 heavy chain constant region (CH2) as potential candidate therapeutics and diagnostics, and discuss examples of eAds against HIV-1 and cancer-related proteins.
Export Options
About this article
Cite this article as:
Chen Weizao, Gong Rui, Ying Tianlei, Prabakaran Ponraj, Zhu Zhongyu, Feng Yang and Dimitrov S. Dimiter, Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains, Current Drug Discovery Technologies 2014; 11 (1) . https://dx.doi.org/10.2174/15701638113109990032
DOI https://dx.doi.org/10.2174/15701638113109990032 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calcium Carbonate Microparticles as Carriers of <sup>224</sup>Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Current Radiopharmaceuticals Subject Index To Volume 1
Current Gene Therapy Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Current Pharmaceutical Biotechnology New Therapeutic Strategies for Castration-Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Atomic Layers in Electrochemical Biosensing Applications - Graphene and Beyond
Current Organic Chemistry Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy Recent Developments in Oxidative Processes in Steroid Chemistry
Current Organic Chemistry Leptin as Clinical Target
Recent Patents on Inflammation & Allergy Drug Discovery Synthesis of Unsymmetrical C5-Curcuminoids as Potential Anticancer Agents
Letters in Drug Design & Discovery MicroRNA Dysregulation in the Myelodysplastic Syndromes
MicroRNA Patent Selections
Recent Patents on Biomarkers Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry Hepatocyte Growth Factor is a Potential Lymphangiogenic Factor; Clinical Implications
Current Signal Transduction Therapy An Overview of Phytochemical and Pharmacological Profile of <i>Morus alba</i> Linn
Current Bioactive Compounds Regulation of Apoptosis and Cell Survival by Resveratrol
Mini-Reviews in Organic Chemistry Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry Understanding and Applying Personalized Therapeutics at Systems Level:Role for Translational Bioinformatics
Current Pharmacogenomics and Personalized Medicine